![Yann Mazabraud](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 7 M $ in data 30/06/2026
Yann Mazabraud is Executive Vice President & Head-International at Rhythm Pharmaceuticals, Inc. since 2020.
Former roles include General Manager-US & Head-North America at Genzyme Corp.
from 2016 to 2017, Head-Latin America at Genzyme Therapeutics Ltd., and Chief Commercial Officer & Head-International at Trevi Therapeutics, Inc. from 2017 to 2020.
Education includes a graduate degree from Groupe de Sup de Co La Rochelle.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 27/04/2026 | 66.030 ( 0,1% ) | 7 M $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05/10/2020 |
| Società | Posizione | Fine |
|---|---|---|
| TREVI THERAPEUTICS, INC. | Corporate Officer/Principal | 03/10/2020 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/10/2017 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Groupe de Sup de Co La Rochelle
 Groupe de Sup de Co La Rochelle Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Therapeutics, Inc.
 Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
